{"id":34884,"date":"2026-03-26T17:38:00","date_gmt":"2026-03-26T12:08:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34884"},"modified":"2026-03-26T13:39:03","modified_gmt":"2026-03-26T08:09:03","slug":"medtech-news-for-liviwell-medtronic-zeiss","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss","title":{"rendered":"LiviWell Receives FDA Clearance for Livi, Pioneering Post-Intercourse Vaginal Care; Medtronic Advances Spine and Cardiac Care with ViaVerte Partnership and FDA Approval of OmniaSecure Lead; ZEISS Broadens Its Ophthalmic Workflow Portfolio in Canada; Starlight Cardiovascular Reports First-Ever Infant Treated with Lifeline Stent System at Cincinnati Children\u2019s Hospital; Belay Diagnostics Highlights 82% Clinical Impact Rate for Summit\u2122 and Vantage\u2122 in CNS Lymphoma"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0913f123c15\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0913f123c15\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss\/#LiviWell_Secured_FDA_Clearance_for_Livi_Introducing_a_New_Category_in_Post-Intercourse_Vaginal_Care\" >LiviWell Secured FDA Clearance for Livi, Introducing a New Category in Post-Intercourse Vaginal Care&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss\/#Medtronic_OmniaSecure_Defibrillation_Lead_the_First_Lead_of_its_Kind_Received_FDA_Approval_for_Conduction_System_Pacing\" >Medtronic OmniaSecure Defibrillation Lead, the First Lead of its Kind, Received FDA Approval for Conduction System Pacing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss\/#ZEISS_Expanded_Ophthalmic_Workflow_Portfolio_in_Canada\" >ZEISS Expanded Ophthalmic Workflow Portfolio in Canada&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss\/#Medtronic_and_Merit_Medical_Systems_Entered_into_Agreement_to_Offer_New_FDA-cleared_ViaVerte_System_a_Basivertebral_Nerve_Ablation_Treatment_for_Chronic_Vertebrogenic_Lower-back_Pain\" >Medtronic and Merit Medical Systems Entered into Agreement to Offer New, FDA-cleared ViaVerte System, a Basivertebral Nerve Ablation Treatment for Chronic Vertebrogenic Lower-back Pain&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss\/#Starlight_Cardiovascular_Announced_the_First_Baby_in_the_World_Treated_with_Lifeline_Stent_System_at_Cincinnati_Childrens_Hospital\" >Starlight Cardiovascular Announced the First Baby in the World Treated with Lifeline Stent System at Cincinnati Children&#8217;s Hospital&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss\/#Belay_Diagnostics_Reported_82_Clinical_Impact_Rate_for_Summit%E2%84%A2_and_Vantage%E2%84%A2_in_CNS_Lymphoma_Study\" >Belay Diagnostics Reported 82% Clinical Impact Rate for Summit\u2122 and Vantage\u2122 in CNS Lymphoma Study&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-liviwell-secured-fda-clearance-for-livi-introducing-a-new-category-in-post-intercourse-vaginal-care-nbsp\"><span class=\"ez-toc-section\" id=\"LiviWell_Secured_FDA_Clearance_for_Livi_Introducing_a_New_Category_in_Post-Intercourse_Vaginal_Care\"><\/span><strong>LiviWell Secured FDA Clearance for Livi, Introducing a New Category in Post-Intercourse Vaginal Care&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 24 March 2026, LiviWell announced that the U.S. Food and Drug Administration had granted clearance for Livi, a novel device developed to support vaginal health by absorbing semen and other post-intercourse fluids.<\/p>\n\n\n\n<p>This regulatory approval represented a key milestone for the company, positioning Livi as a first-of-its-kind solution in the intimate health space. The device was designed for vaginal insertion after intercourse, where it functioned to quickly absorb fluids, typically within about 60 seconds. It was constructed from soft polyurethane foam and came with an applicator similar to a tampon for ease of use. The single-use device could be worn for up to 15 minutes post-intercourse before removal.<\/p>\n\n\n\n<p><em>&#8220;Receiving FDA clearance for Livi marks a defining milestone for LiviWell and signals the introduction of a new category in women&#8217;s intimate health,&#8221; said Dawn Halkuff, Chief Executive Officer of LiviWell. &#8220;For too long, the realities women experience after sex have gone largely unaddressed by innovation. This clearance allows us to bring a simple, easy-to-use solution to market &#8211; one that fits seamlessly into a woman&#8217;s routine and helps her feel more comfortable and confident.&#8221;<\/em><\/p>\n\n\n\n<p><em>&#8220;From a clinical perspective, many patients have questions about post-sex complaints such as discharge and odor,&#8221; said Dr. Michael Ingber, MD, board-certified urogynecologist, Co-Founder and Chief Medical Officer of LiviWell. &#8220;Our research has shown that semen disrupts vaginal pH and can contribute to those common post-intercourse complaints. Conversations around post-sex vaginal health have historically been limited. Achieving FDA clearance for Livi represents an important step toward bringing greater medical recognition and innovative solutions to women experiencing these everyday concerns.&#8221;<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/femtech-market\"><strong>FemTech Market Report<\/strong><\/a>,\u201d the global femtech market is estimated to grow at a <strong>CAGR of 13.52%<\/strong> during the forecast period from 2025 to 2032. The demand for femtech is being boosted by a rise in the adoption of digital health solutions, advancement in artificial intelligence and virtual assistance, growth in investments and funding, growing female awareness of personal health and hygiene, rising infectious diseases among women, large investments made by the government and other organizations, among others are thereby contributing to the overall growth of the femtech market during the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-medtronic-omniasecure-defibrillation-lead-the-first-lead-of-its-kind-received-fda-approval-for-conduction-system-pacing\"><span class=\"ez-toc-section\" id=\"Medtronic_OmniaSecure_Defibrillation_Lead_the_First_Lead_of_its_Kind_Received_FDA_Approval_for_Conduction_System_Pacing\"><\/span><strong>Medtronic OmniaSecure Defibrillation Lead, the First Lead of its Kind, Received FDA Approval for Conduction System Pacing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 24 March 2026, Medtronic plc announced that it had received approval from the U.S. Food and Drug Administration for an expanded indication of its OmniaSecure\u2122 defibrillation lead. The approval allowed the device to be used in the left bundle branch (LBB) area, enabling conduction system pacing (CSP), a method that more closely replicates the heart\u2019s natural electrical activity.<\/p>\n\n\n\n<p>This milestone made OmniaSecure the first defibrillation lead approved for placement in the LBB region. Designed to connect with implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), the lead was developed to manage life-threatening arrhythmias such as ventricular tachycardia, ventricular fibrillation, and bradyarrhythmias. Its compact design (4.7 French) made it the smallest defibrillation lead available, and it was approved for both adults and pediatric patients aged 12 years and older.<\/p>\n\n\n\n<p>Built on the foundation of the SelectSecure Model 3830 pacing lead, the OmniaSecure lead featured a lumenless structure that enhanced durability and enabled catheter-based delivery for precise placement. By leveraging CSP, the device could activate the heart\u2019s intrinsic conduction pathways, potentially reducing complications associated with conventional pacing approaches.<\/p>\n\n\n\n<p>The approval was supported by findings from the LEADR LBBAP trial, which demonstrated strong safety and efficacy outcomes, including a 100% defibrillation success rate at implantation and a low complication rate at three months. The therapy could also be combined with left ventricular pacing in advanced approaches such as LOT-CRT to further improve synchronization and patient outcomes.<\/p>\n\n\n\n<p><em>&#8220;Conduction system pacing is a rapidly growing therapy for patients who need a pacemaker. Now, patients who require a defibrillator and pacing have an option that can safely deliver life-saving defibrillation therapy and activate the heart&#8217;s natural electrical system to enable a more synchronous, physiologic pattern,&#8221; said Trevor Cook, vice president and general manager of the Defibrillation Solutions business, which is part of the Cardiac Rhythm Management operating unit at Medtronic. &#8220;This approval underscores the versatility of the OmniaSecure defibrillation lead and supports its use across a variety of implant approaches to best serve a broad range of patients.&#8221;<\/em>&nbsp;<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/defibrillator-market\"><strong>Defibrillators Market Report<\/strong><\/a>,\u201d the defibrillators market was valued at <strong>USD 10.19 billion<\/strong> in 2023, growing at a <strong>CAGR of 3.11%<\/strong> during the forecast period from 2025 to 2032, to reach <strong>USD 12.24 billion<\/strong> by 2032. The defibrillator market is observing substantial market growth, primarily owing to the increasing cases of chronic disorders such as cardiovascular diseases, including atrial fibrillation and coronary artery disease (CAD), innovative product development activities by leading companies, and the rising geriatric population, which are expected to escalate the overall growth of the defibrillators market during the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-zeiss-expanded-ophthalmic-workflow-portfolio-in-canada-nbsp\"><span class=\"ez-toc-section\" id=\"ZEISS_Expanded_Ophthalmic_Workflow_Portfolio_in_Canada\"><\/span><strong>ZEISS Expanded Ophthalmic Workflow Portfolio in Canada&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 24 March 2026, ZEISS Medical Technology announced the expansion of its ophthalmology and optometry clinical workflows in Canada, introducing advanced diagnostic systems, next-generation laser treatment devices, and enhanced digital workflow solutions. These innovations were showcased at major industry events, including the Ontario Association of Optometrists conference and the Canadian Ophthalmological Society conference.<\/p>\n\n\n\n<p>The company enhanced its imaging capabilities with the CLARUS\u00ae 700, adding features such as advanced angiography modes and ultra-widefield imaging for retina and glaucoma care. It also expanded its therapeutic portfolio with the VISULAS\u00ae green laser for glaucoma and retinal treatments, along with the VISULAS\u00ae yag laser for anterior segment procedures within cataract workflows.<\/p>\n\n\n\n<p>Additionally, ZEISS introduced new diagnostic tools like the VISUREF\u00ae 600 and VISUCORE 500, designed to streamline refraction workflows and improve clinical efficiency. The rollout also included the FORUM\u00ae digital platform, enabling centralized data management and fully paperless clinical workflows. Overall, the expansion strengthened ZEISS\u2019s presence in Canada by improving clinical efficiency, enhancing patient care, and advancing digital integration in eye care practices.&nbsp;<\/p>\n\n\n\n<p><em>&#8220;ZEISS is proud to expand access to advanced therapeutic lasers, diagnostic technologies, and digital workflow solutions in Canada. These innovations help enhance patient care across our clinical workflows and reflect our commitment to supporting eye care professionals with integrated solutions which offer tools that support them in making informed care decisions, improving practice efficiency, and delivering better outcomes for patients across the country,&#8221; says Bryan Rossi, President of ZEISS Canada.<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/ophthalmic-devices-market\"><strong>Ophthalmic Devices Market Report<\/strong><\/a>,\u201d the global ophthalmic devices market is expected to increase from <strong>USD 31,902.50 million <\/strong>in 2024 to <strong>USD 44,247.53 million<\/strong> by 2032, growing at a <strong>CAGR of 7.13%<\/strong> during the forecast period from 2025 to 2032. The global ophthalmic device market is witnessing robust growth, primarily driven by the rising incidence of eye disorders such as cataracts, glaucoma, age-related macular degeneration, diabetic retinopathy, and refractive errors. Factors such as aging populations, increasing prevalence of diabetes and hypertension, and greater exposure to digital screens are significantly contributing to the growing patient pool. This surge in eye-related conditions is fueling demand for advanced diagnostic, surgical, and vision correction devices, prompting continuous innovation and adoption of technologies like minimally invasive surgeries, laser systems, and AI-enabled diagnostics. Consequently, the escalating burden of eye diseases is a key catalyst shaping the expansion of the ophthalmic device market worldwide.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-medtronic-and-merit-medical-systems-entered-into-agreement-to-offer-new-fda-cleared-viaverte-system-a-basivertebral-nerve-ablation-treatment-for-chronic-vertebrogenic-lower-back-pain-nbsp\"><span class=\"ez-toc-section\" id=\"Medtronic_and_Merit_Medical_Systems_Entered_into_Agreement_to_Offer_New_FDA-cleared_ViaVerte_System_a_Basivertebral_Nerve_Ablation_Treatment_for_Chronic_Vertebrogenic_Lower-back_Pain\"><\/span><strong>Medtronic and Merit Medical Systems Entered into Agreement to Offer New, FDA-cleared ViaVerte System, a Basivertebral Nerve Ablation Treatment for Chronic Vertebrogenic Lower-back Pain&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 24 March 2026, Medtronic plc announced that it had entered into a distribution agreement with Merit Medical Systems, Inc. to offer the FDA-cleared ViaVerte\u2122 system, a minimally invasive and implant-free basivertebral nerve ablation (BVNA) technology.<\/p>\n\n\n\n<p>This system was recognized as the first and only BVNA solution featuring a physician-controlled steerable mechanism, enabling precise targeting of the basivertebral nerve for the treatment of chronic vertebrogenic lower back pain. The agreement marked another strategic step for Medtronic in strengthening its core business areas and further expanding its collaboration with Merit Medical.<\/p>\n\n\n\n<p>Merit had already been a supplier for Medtronic, providing products such as the Kyphon\u2122 Xpander\u2122 Inflation Syringes and Kyphon\u2122 KyphoFlex\u2122 steerable balloon catheter, which are used in procedures for vertebral compression fractures. The addition of ViaVerte\u2122 complemented Medtronic\u2019s existing pain management portfolio.<\/p>\n\n\n\n<p>With chronic pain affecting a significant portion of the population, the ViaVerte\u2122 system was positioned as a growing therapeutic option. It was designed to offer a minimally invasive, same-day outpatient procedure, aligning with Medtronic\u2019s objective of expanding access to innovative and effective pain treatment solutions.<\/p>\n\n\n\n<p><em>&#8220;For 50 years, we have advanced how chronic pain is treated,&#8221; said Paolo Di Vincenzo, president, Medtronic Neuromodulation, which is part of the Medtronic Neuroscience Portfolio. &#8220;Adding ViaVerte\u2122 Basivertebral Nerve Ablation expands our world-leading pain interventions portfolio and gives patients and their physicians another meaningful option for lasting relief. 2,3&#8221;<\/em><\/p>\n\n\n\n<p><em>&#8220;We are thrilled to expand our ongoing business relationship with Medtronic by providing Merit&#8217;s proprietary articulating technology,&#8221; said Michael Blackham, executive vice president, Global OEM, Merit Medical Systems, Inc. &#8220;We believe ViaVerte\u2122 represents a significant advancement in the BVNA market.&#8221;<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/pain-management-devices-market\"><strong>Pain Management Devices Market Report<\/strong><\/a>\u201d, the global pain management devices market is expected to increase from <strong>USD 5,277.30 million<\/strong> in 2024 to <strong>USD 9,350.72 million<\/strong> by 2032, growing at a <strong>CAGR of 7.53%<\/strong> during the forecast period from 2025 to 2032. The global pain management devices market is set to grow rapidly from 2025 to 2032, driven by the rising prevalence of chronic pain, frequent product launches, and increasing awareness of pain management solutions. Growing demand for minimally invasive devices and supportive awareness campaigns are boosting adoption, creating strong opportunities for innovation and improved patient outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-starlight-cardiovascular-announced-the-first-baby-in-the-world-treated-with-lifeline-stent-system-at-cincinnati-children-s-hospital-nbsp\"><span class=\"ez-toc-section\" id=\"Starlight_Cardiovascular_Announced_the_First_Baby_in_the_World_Treated_with_Lifeline_Stent_System_at_Cincinnati_Childrens_Hospital\"><\/span><strong>Starlight Cardiovascular Announced the First Baby in the World Treated with Lifeline Stent System at Cincinnati Children&#8217;s Hospital&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 24 March 2026, Starlight Cardiovascular announced that the first infant in the world had been treated using its Lifeline\u2122 Ductus Arteriosus Stent System at Cincinnati Children&#8217;s Hospital in January. The procedure was conducted as part of a clinical study under the U.S. Food and Drug Administration Investigational Device Exemption (IDE) program.<\/p>\n\n\n\n<p>The intervention was performed by Dr. Shabana Shahanavaz on an 8-day-old infant diagnosed with complex congenital heart defects, including Double Inlet Left Ventricle and Pulmonary Atresia, conditions that severely restrict blood flow to the lungs. The Lifeline\u2122 stent was specifically designed to keep the ductus arteriosus open\u2014a temporary fetal blood vessel that typically closes after birth, thereby ensuring adequate pulmonary blood circulation in critical cases.<\/p>\n\n\n\n<p>Unlike conventional approaches that often require high-risk open-heart surgery or the use of adult-designed stents, the Lifeline\u2122 system offered a minimally invasive alternative tailored for neonatal anatomy. Its flexible design enabled it to adapt to the highly curved structure of the ductus arteriosus, improving safety and ease of use. The clinical trial was led by Dr. Aimee Armstrong from Nationwide Children\u2019s Hospital, who highlighted its potential advantages over existing treatment options.&nbsp;<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201d<a href=\"https:\/\/www.delveinsight.com\/report-store\/interventional-cardiology-devices-market\"><strong>Interventional Cardiology Devices\u00a0Market Report<\/strong><\/a>,\u201d The global interventional cardiology devices market is expected to increase from <strong>USD 20,192.60 million<\/strong> in 2024 to <strong>USD 34,866.30 million<\/strong> by 2032, growing at a <strong>CAGR of 7.09%<\/strong> during the forecast period from 2025 to 2032. The global interventional cardiology devices market is driven by the growing prevalence of cardiovascular diseases (CVDs) and their associated risk factors, increasing preference for minimally invasive procedures, increasing technological advancement in product design, and an increase in strategic activities among the key market players.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-belay-diagnostics-reported-82-clinical-impact-rate-for-summit-and-vantage-in-cns-lymphoma-study-nbsp\"><span class=\"ez-toc-section\" id=\"Belay_Diagnostics_Reported_82_Clinical_Impact_Rate_for_Summit%E2%84%A2_and_Vantage%E2%84%A2_in_CNS_Lymphoma_Study\"><\/span><strong>Belay Diagnostics Reported 82% Clinical Impact Rate for Summit\u2122 and Vantage\u2122 in CNS Lymphoma Study&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 24 March 2026, Belay Diagnostics announced that a retrospective study had been published demonstrating the clinical value of its Summit and Vantage tests in patients with central nervous system (CNS) lymphoma. The study evaluated 50 specimens from 48 patients during the first year of the tests\u2019 commercial availability and found that the assays delivered meaningful clinical impact in 82% of cases.<\/p>\n\n\n\n<p>The findings showed that the tests had helped clinicians address key diagnostic challenges, including resolving uncertain differential diagnoses, confirming disease recurrence or progression, supporting disease stratification, and assisting in clinical trial decision-making where traditional diagnostic tools had limited sensitivity. In 64% of the samples, Summit successfully identified clinically relevant genetic variants, while negative results also proved useful in ruling out CNS lymphoma or confirming treatment response.<\/p>\n\n\n\n<p>Notably, in one highlighted case, Summit was the only test that provided actionable insights after other diagnostic methods, such as MRI, biopsy, and blood-based testing, had yielded inconclusive results. The study also identified key genetic alterations, including MYD88, TP53, and CD79B, which are strongly associated with CNS lymphoma. Additionally, findings related to aneuploidy helped indicate potential metastatic disease in certain cases, while longitudinal monitoring demonstrated treatment effectiveness through the absence of previously detected variants.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/molecular-diagnostics-market\"><strong>Molecular Diagnostics Market Report<\/strong><\/a>,\u201d&nbsp; the molecular diagnostics market was valued at <strong>USD 9.56 billion<\/strong> in 2024, growing at a <strong>CAGR of 9.21% <\/strong>during the forecast period from 2025 to 2032, to reach <strong>USD 16.12 billion<\/strong> by 2032. The molecular diagnostics market is experiencing significant growth due to the increasing cases of infectious diseases, including HIV, Hepatitis B, Hepatitis C, Influenza, and human papillomavirus (HPV). The introduction of new and innovative products by key Molecular Diagnostics Companies, among others, is expected to drive the Molecular Diagnostics Market from 2025 to 2032.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>LiviWell Secured FDA Clearance for Livi, Introducing a New Category in Post-Intercourse Vaginal Care&nbsp; On 24 March 2026, LiviWell announced that the U.S. Food and Drug Administration had granted clearance for Livi, a novel device developed to support vaginal health by absorbing semen and other post-intercourse fluids. This regulatory approval represented a key milestone for [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34885,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[21540,21101,19292,2753,17021,19145,19459,21247],"industry":[17226],"therapeutic_areas":[17242,17244],"class_list":["post-34884","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-defibrillators","tag-femtech","tag-interventional-cardiology-devices-market","tag-medical-device","tag-medical-devices-market","tag-molecular-diagnostics","tag-ophthalmic-devices","tag-pain-management-devices","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | LiviWell, Medtronic, ZEISS<\/title>\n<meta name=\"description\" content=\"LiviWell\u2019s Livi; Medtronic\u2019s OmniaSecure; ZEISS\u2019 Ophthalmic Workflow Portfolio; Medtronic and Merit Medical Systems\u2019 Agreement\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | LiviWell, Medtronic, ZEISS\" \/>\n<meta property=\"og:description\" content=\"LiviWell\u2019s Livi; Medtronic\u2019s OmniaSecure; ZEISS\u2019 Ophthalmic Workflow Portfolio; Medtronic and Merit Medical Systems\u2019 Agreement\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-26T12:08:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/medtech-news-for-liviwell-medtronic-zeiss.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | LiviWell, Medtronic, ZEISS","description":"LiviWell\u2019s Livi; Medtronic\u2019s OmniaSecure; ZEISS\u2019 Ophthalmic Workflow Portfolio; Medtronic and Merit Medical Systems\u2019 Agreement","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss","og_locale":"en_US","og_type":"article","og_title":"MedTech News | LiviWell, Medtronic, ZEISS","og_description":"LiviWell\u2019s Livi; Medtronic\u2019s OmniaSecure; ZEISS\u2019 Ophthalmic Workflow Portfolio; Medtronic and Merit Medical Systems\u2019 Agreement","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-03-26T12:08:00+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/medtech-news-for-liviwell-medtronic-zeiss.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss","name":"MedTech News | LiviWell, Medtronic, ZEISS","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/medtech-news-for-liviwell-medtronic-zeiss.webp","datePublished":"2026-03-26T12:08:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"LiviWell\u2019s Livi; Medtronic\u2019s OmniaSecure; ZEISS\u2019 Ophthalmic Workflow Portfolio; Medtronic and Merit Medical Systems\u2019 Agreement","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-liviwell-medtronic-zeiss#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/medtech-news-for-liviwell-medtronic-zeiss.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/medtech-news-for-liviwell-medtronic-zeiss.webp","width":772,"height":482,"caption":"medtech-news-for-liviwell-medtronic-zeiss"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/medtech-news-for-liviwell-medtronic-zeiss-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Defibrillators<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FemTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Interventional Cardiology Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Molecular Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ophthalmic Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pain Management Devices<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Defibrillators<\/span>","<span class=\"advgb-post-tax-term\">FemTech<\/span>","<span class=\"advgb-post-tax-term\">Interventional Cardiology Devices Market<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Molecular Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Ophthalmic Devices<\/span>","<span class=\"advgb-post-tax-term\">Pain Management Devices<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 months ago","modified":"Updated 2 months ago"},"absolute_dates":{"created":"Posted on Mar 26, 2026","modified":"Updated on Mar 26, 2026"},"absolute_dates_time":{"created":"Posted on Mar 26, 2026 5:38 pm","modified":"Updated on Mar 26, 2026 1:39 pm"},"featured_img_caption":"medtech-news-for-liviwell-medtronic-zeiss","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34884"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34884\/revisions"}],"predecessor-version":[{"id":34886,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34884\/revisions\/34886"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34885"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34884"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34884"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}